YC-1 enhances the anti-tumor activity of sorafenib through inhibition of signal transducer and activator of transcription 3 (STAT3) in hepatocellular carcinoma.
about
TCAB1: a potential target for diagnosis and therapy of head and neck carcinomasYC-1 induces G0/G1 phase arrest and mitochondria-dependent apoptosis in cisplatin-resistant human oral cancer CAR cellsAlteration of SHP-1/p-STAT3 Signaling: A Potential Target for Anticancer Therapy.Fructopyrano-(1→4)-glucopyranose inhibits the proliferation of liver cancer cells and angiogenesis in a VEGF/VEGFR dependent manner.The naturally born fusariotoxin enniatin B and sorafenib exert synergistic activity against cervical cancer in vitro and in vivo.Down-regulation of STAT3 expression using vector-based RNA interference promotes apoptosis in Hepatocarcinoma cells.Sorafenib suppresses the epithelial-mesenchymal transition of hepatocellular carcinoma cells after insufficient radiofrequency ablation.Indole-3- carbinol enhances sorafenib cytotoxicity in hepatocellular carcinoma cells: A mechanistic studySorafenib with ASC-J9® synergistically suppresses the HCC progression via altering the pSTAT3-CCL2/Bcl2 signals.Implication of protein tyrosine phosphatase SHP-1 in cancer-related signaling pathways.Promising new strategies for hepatocellular carcinoma.Interferon-α inhibits cell migration and invasion and induces the expression of antiviral proteins in Huh-7 cells transfected with hepatitis B virus X gene-expressing lentivirus.Long noncoding RNA-SRLR elicits intrinsic sorafenib resistance via evoking IL-6/STAT3 axis in renal cell carcinoma.TAT-OSBP-1-MKK6(E), a novel TAT-fusion protein with high selectivity for human ovarian cancer, exhibits anti-tumor activity.ATPase inhibitory factor 1 inhibition improves the antitumor of YC-1 against hepatocellular carcinoma
P2860
Q21245751-6E481B34-2D37-4FB1-8B77-C0DC76D8B3AAQ33821469-070A2AEA-E4EE-47DA-9E88-EEB4D3F58C87Q33838824-6E2BDEE8-F913-48D4-BD34-4EE496105DC9Q34769751-A35057D6-2FBC-4EB0-8A3E-159ACB8E23D4Q35232168-C167A803-62C3-4E50-AE05-263EB74A12CAQ35680848-F2D9E41D-3482-4353-B56B-27B87C3BD88CQ35856250-049A9BC3-EC9B-454B-B61E-96AB22CCDFB3Q37244398-66AA0AB9-CF7C-46A8-9521-C70BDFF5823DQ38743727-805A7D14-0072-4DA1-9B63-7964562C1E63Q38778743-068D2F03-A2FC-4439-A4C2-283CBCEFE970Q38936589-75F4133F-389F-46EF-9B0A-9B3A8AEDEF95Q47149904-0F04A5BE-0592-4CB2-9060-6BCA7E1F87ECQ51328387-F0C267DA-2920-41E6-A0C9-552A04155CDCQ52958205-CC2806DC-4E55-461F-A635-5F6F304CD48FQ58800845-83AA650B-84F8-4591-9234-6975E5ED3049
P2860
YC-1 enhances the anti-tumor activity of sorafenib through inhibition of signal transducer and activator of transcription 3 (STAT3) in hepatocellular carcinoma.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 13 January 2014
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
YC-1 enhances the anti-tumor a ...... ) in hepatocellular carcinoma.
@en
YC-1 enhances the anti-tumor a ...... d activator of transcription 3
@nl
type
label
YC-1 enhances the anti-tumor a ...... ) in hepatocellular carcinoma.
@en
YC-1 enhances the anti-tumor a ...... d activator of transcription 3
@nl
prefLabel
YC-1 enhances the anti-tumor a ...... ) in hepatocellular carcinoma.
@en
YC-1 enhances the anti-tumor a ...... d activator of transcription 3
@nl
P2093
P2860
P356
P1433
P1476
YC-1 enhances the anti-tumor a ...... ) in hepatocellular carcinoma.
@en
P2093
Fandong Kong
Huichuan Sun
Lemin Zheng
Qiang Shen
Qiangbo Zhang
P2860
P2888
P356
10.1186/1476-4598-13-7
P577
2014-01-13T00:00:00Z
P5875
P6179
1018876961